Details for New Drug Application (NDA): 205353
✉ Email this page to a colleague
NDA 205353 describes FARYDAK, which is a drug marketed by Secura and is included in one NDA. It is available from one supplier. There are two patents protecting this drug. Additional details are available on the FARYDAK profile page.
The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the panobinostat lactate profile page.
The generic ingredient in FARYDAK is panobinostat lactate. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the panobinostat lactate profile page.
Summary for 205353
| Tradename: | FARYDAK |
| Applicant: | Secura |
| Ingredient: | panobinostat lactate |
| Patents: | 2 |
DrugPatentWatch® Estimated Generic Entry Opportunity Date for 205353
Generic Entry Date for 205353*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 205353
| Mechanism of Action | Cytochrome P450 2D6 Inhibitors Histone Deacetylase Inhibitors |
Suppliers and Packaging for NDA: 205353
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| FARYDAK | panobinostat lactate | CAPSULE;ORAL | 205353 | NDA | Novartis Pharmaceuticals Corporation | 0078-0650 | 0078-0650-06 | 6 CAPSULE in 1 BLISTER PACK (0078-0650-06) |
| FARYDAK | panobinostat lactate | CAPSULE;ORAL | 205353 | NDA | Novartis Pharmaceuticals Corporation | 0078-0651 | 0078-0651-06 | 6 CAPSULE in 1 BLISTER PACK (0078-0651-06) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;ORAL | Strength | EQ 10MG BASE | ||||
| Approval Date: | Feb 23, 2015 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Feb 23, 2022 | ||||||||
| Regulatory Exclusivity Use: | TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 2 PRIOR REGIMENS, INCLUDING BORTEZOMIB AND AN IMMUNOMODULATORY AGENT | ||||||||
| Patent: | See Plans and Pricing | Patent Expiration: | Jan 17, 2028 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | See Plans and Pricing | Patent Expiration: | Jun 13, 2028 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF MULTIPLE MYELOMA, IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE | ||||||||
Expired US Patents for NDA 205353
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Secura | FARYDAK | panobinostat lactate | CAPSULE;ORAL | 205353-001 | Feb 23, 2015 | See Plans and Pricing | See Plans and Pricing |
| Secura | FARYDAK | panobinostat lactate | CAPSULE;ORAL | 205353-001 | Feb 23, 2015 | See Plans and Pricing | See Plans and Pricing |
| Secura | FARYDAK | panobinostat lactate | CAPSULE;ORAL | 205353-003 | Feb 23, 2015 | See Plans and Pricing | See Plans and Pricing |
| Secura | FARYDAK | panobinostat lactate | CAPSULE;ORAL | 205353-002 | Feb 23, 2015 | See Plans and Pricing | See Plans and Pricing |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
